Clinical Trial Update: Safety of CRIS100 on Treatment Spinal Cord Injury [EARLY_Phase 1]

View source ↗

Summary

The document provides safety information for CRIS100 in an early-phase trial for thoracic spinal cord injury. The study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Cord Injury

Drugs mentioned

• CRIS100

Snippet

Sponsor: Cristália Produtos Químicos Farmacêuticos Ltda. | Conditions: Thoracic Spinal Cord Injury | EARLY_Phase 1 | Status: NOT_YET_RECRUITING